Despite grim predictions of rate shock, older and sicker people will experience 'rate joy' in the exchanges
In 2014, as many as 7 million individuals will have exchange coverage, with some enrollees experiencing the forewarned rate shock and others experiencing rate "joy,” according to Princeton University economist Uwe Reinhardt, speaking at an Alliance for Health Reform web conference last month.
Reinhardt says it’s difficult to accurately compare the exchange rates to prevailing rates because the underlying methodology would be based on assumptions. Even so, to focus only on rate shock is to leave out half the story.
“The premium shock for many people might be lower or might actually be ‘premium joy,’” he says, especially for older or sicker individuals who would benefit from modified community rating.
Three key elements of health reform-guaranteed issue, the individual mandate and subsidies for low-income enrollees-help balance the individual market. While forecasts tend to indicate large premium increases, many of the recent predictions don’t figure in subsidies. For example, the Ohio insurance commissioner last month projected individual health plan coverage would increase by 41% on average.
“It’s very difficult to predict the winners and losers without knowing their income and subsidy level,” Reinhardt says.
Poor but healthy individuals might be the net winners based on subsidized premiums. But the key to rates could well be the composition of the risk pool-if enough healthy people join, rates could be lower than expected.
He says rates will vary by geographic region and whether the exchange adopts a passive model or an active-purchaser model. In time, insurers will also readjust premiums based on their experiences in the exchanges.
Tom Miller, resident fellow, the American Enterprise Institute, also speaking at the conference, believes health reform is creating a more expensive system.
“The costs are going up, and just because payment is reshuffled doesn’t mean they’re going to be reduced,” Miller says.
Whether individuals and families lose or gain in the future by purchasing on the insurance exchanges could depend a lot on their current premiums-assuming they are able to obtain coverage. The Government Accountability Office (GAO) reports that 19% of applicants are denied coverage in the underwriting process.
With health reform, no one can be denied coverage, and that alone could be considered an advantage, says Linda Blumberg, senior fellow, the Urban Institute.
“The non-group market has been the most dysfunctional market we’ve had,” Blumberg says.
A brief from actuarial firm Milliman predicts that in Indiana average market premium rates will rise by 75% to 95%, not including subsidies. The brief also notes that those currently purchasing plans with an actuarial level above 60% will be less impacted by the cost difference in the exchange market, and those who are older or in poor health are likely to experience decreases.
A July report from the GAO breaks down the baseline of pre-reform premiums by state reported in January 2013, prior to underwriting. While not all insurers reported-roughly 20% did not submit data-and not all plans had significant enrollment, the variation in rates is apparent.
New York and New Jersey reported the highest annual premiums for individuals and families, according to the GAO. The lowest annual premium reported for a 30-year old male non-smoker was in Nebraska at $349. The plan also has a $5,000 deductible and $10,000 out-of-pocket maximum.
Blumberg says, however, the products individuals can buy today aren’t the same as the products offered in the exchanges. Exchange plans must lower the amount of out-of-pocket costs for essential benefits for enrollees at certain income levels, for example.
The expectation among reform advocates is that the exchanges will right a number of wrongs in the non-group market, including skimpy benefits, unaffordable premiums and scant plan choices.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More